A detailed history of Ubs Group Ag transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 80,289 shares of FDMT stock, worth $506,623. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,289
Previous 67,140 19.58%
Holding current value
$506,623
Previous $1.41 Million 38.47%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.81 - $27.22 $142,140 - $357,915
13,149 Added 19.58%
80,289 $867,000
Q2 2024

Aug 13, 2024

SELL
$20.93 - $30.01 $6.43 Million - $9.21 Million
-307,050 Reduced 82.06%
67,140 $1.41 Million
Q1 2024

May 13, 2024

BUY
$17.03 - $35.87 $4.91 Million - $10.3 Million
288,139 Added 334.85%
374,190 $11.9 Million
Q4 2023

Feb 09, 2024

BUY
$9.76 - $21.25 $401,663 - $874,522
41,154 Added 91.66%
86,051 $1.74 Million
Q3 2023

Nov 09, 2023

SELL
$12.64 - $19.76 $113,165 - $176,911
-8,953 Reduced 16.63%
44,897 $571,000
Q2 2023

Aug 11, 2023

BUY
$15.16 - $23.26 $21,997 - $33,750
1,451 Added 2.77%
53,850 $973,000
Q1 2023

May 12, 2023

BUY
$15.45 - $23.19 $180,316 - $270,650
11,671 Added 28.66%
52,399 $900,000
Q4 2022

Feb 08, 2023

BUY
$6.85 - $25.46 $278,986 - $1.04 Million
40,728 New
40,728 $904,000
Q2 2022

Aug 10, 2022

SELL
$5.68 - $15.99 $398,730 - $1.12 Million
-70,199 Reduced 99.95%
35 $0
Q1 2022

May 16, 2022

BUY
$13.16 - $22.64 $11,633 - $20,013
884 Added 1.27%
70,234 $1.06 Million
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $1.33 Million - $2.24 Million
68,094 Added 5421.5%
69,350 $1.52 Million
Q3 2021

Nov 15, 2021

BUY
$22.73 - $36.04 $28,548 - $45,266
1,256 New
1,256 $34,000
Q2 2021

Aug 13, 2021

SELL
$22.2 - $42.29 $457,142 - $870,835
-20,592 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$35.94 - $52.67 $740,076 - $1.08 Million
20,592 New
20,592 $893,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $204M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.